NTRK1 and lip and oral cavity carcinoma: Use of receptor tyrosine kinase inhibitors like imatinib have been shown to improve responsiveness to doxorubicin through modulation of AKT signaling in head and neck cancer cells (48), suggesting small molecules like crenolanib may offer therapeutic value in patients with PDGFR-α+ oral cancers.